RNK Health Review

RNK Health LLC operates the website, intake, account, payment, and administrative platform. The terms say RNK does not practice medicine or pharmacy, does not employ the treating professionals, and does not control clinical decisions.

Clinical care may come from OpenLoop Healthcare Partners, PC and named affiliated professional entities in particular jurisdictions, or from M & D Integrations Inc. doing business as MD Integrations and its affiliated professional entities. The product, state, availability, and clinical pathway determine which entity participates.

Telehealth may use live video, audio, telephone, secure messaging, an asynchronous questionnaire, or a combination. The clinician decides whether the available information is sufficient, whether another encounter is needed, and whether any prescription is appropriate.

RNK limits the platform to adults in the United States. The terms describe service in all 50 states, but that statement is subject to individual clinician licenses, pharmacy shipping ability, product-specific restrictions, and clinical eligibility. It should not be read as a promise that every treatment is offered to every resident.

The normalized catalog contains seven cards across three AllyRx therapy groups. A route change is preserved when RNK lets the patient choose injectable, nasal, or oral liposomal NAD+. A marketing bundle, dosing promise, benefit label, or diagnostic service does not become a separate medication.

The NAD+ page offers injection, nasal spray, and liposomal liquid as separate selections. Each route displays a monthly plan at $169, a three-month total of $447, and a six-month total of $774, with monthly shipment language for the prepaid terms.

Converting the NAD+ totals to monthly equivalents produces $169, $149, and $129. The simple average is $149 per month. Exact totals and billing cadences remain in the notes so the compact figure does not imply that every customer pays $149 each month.

The NAD+ pages do not publish enough detail for a dose-level comparison. Concentration, fill volume, total amount dispensed, additives, beyond-use date, and patient-specific directions remain unavailable on the public selection page. The injectable page also does not establish the anatomical injection technique.

Sermorelin is offered as an injection on the current product URL. It uses the same $169 monthly, $447 three-month, and $774 six-month structure, producing the same $149 average monthly equivalent. Exact strength, quantity, injection technique, and pharmacy remain undisclosed.

B12-MIC is marketed as a weekly 1,000-microgram injection for $97 per month. RNK does not define every substance represented by MIC or publish the exact injection route, so the review does not infer methionine, inositol, choline, or any other ingredient from the acronym.

The semaglutide page shows a vial labeled as compounded GLP-1 medication, depicts injection supplies, and lists $197 monthly. It does not publish concentration, fill quantity, titration schedule, additives, salt form, assigned pharmacy, or a complete dose-based cost.

The tirzepatide page similarly depicts a vial and injection supplies and lists $297 monthly. Another RNK page displays $347 struck through with a $50 reduction, but no ordinary-price history or duration supports using the anchor or customer promotion in a durable comparison.

The enclomiphene page identifies daily oral capsules and lists $189 monthly. It does not publish the capsule strength, count, laboratory panel, refill cadence, or complete payable amount. The oral route is preserved, while unsupported hormone-outcome promises remain qualified.

RNK also offers a naltrexone program for alcohol use disorder at $89 per month and limits that program to ages 21 through 74. It is acknowledged for catalog completeness but not turned into an AllyRx card because substance-use treatment is outside the site's current editorial scope.

DNA Blueprint is advertised at a $399 one-time price. It is a test and report rather than a prescribed treatment, so it remains outside therapy normalization and medication price comparison.

Product pages repeatedly say everything is included or that there are no hidden fees. The refund policy also describes a single price covering consultation, medication, laboratories when required, support, and related services.

The operative terms create a material qualification. They say RNK access fees are separate from the cost of medication, dispensing, and shipping, and that those charges may be collected by or for the pharmacy. Because the public checkout total is not established, every card remains outside direct price comparison.

Plans may use monthly, quarterly, or annual billing. Unless canceled, the selected subscription continues and rebills. Periodic questionnaires, clinical follow-up, or refill approval may still be required and a prescription is never guaranteed.

RNK says it sends a renewal reminder seven days before the next charge. Cancellation is available in the portal or by contacting support through email or phone, but the request must arrive at least 72 hours before billing. Access ordinarily continues through the paid cycle.

Renewal and rebill charges are generally final and nonrefundable. A patient found medically ineligible may qualify for return of an unused portion, and approved refunds are described as processing within ten business days. The exact amount depends on the reason, timing, and services already used.

Damaged, incorrect, or undelivered orders generally receive replacement first. RNK asks for notice and supporting photographs within seven days where applicable; a refund becomes the alternative only when replacement is unavailable. Product dissatisfaction, dosing expectations, or lack of hoped-for results ordinarily does not qualify.

RNK markets fast private shipping and the homepage references delivery in as little as 48 hours. The terms instead place carrier selection, tracking, temperature handling, timing, and replacement rules under the dispensing pharmacy's control and do not promise a universal dispatch or arrival time.

The footer publishes a pharmacy-support phone number and a Springville, Utah address. It does not name the pharmacy connected to those details or promise that this is the pharmacy assigned to each patient. The review therefore does not convert the contact block into a verified dispensing-pharmacy identity.

Support options include the member portal, email, text, an RNK phone number, and a separate pharmacy-support number. The refund policy refers to a continuously available patient-support line, but no public staffing definition, clinical escalation path, or response-time commitment substantiates that phrase.

RNK says it acts as a business associate when it handles protected health information for covered professional entities. Medical information may be shared with the selected professional entity and pharmacy according to the chosen service, state, and fulfillment needs.

The broader privacy policy also covers contact, commercial, browsing, device, and inferred information for analytics and advertising. It references Google Analytics, cross-context activity, cookie controls, and targeted-advertising choices, and says browser Do Not Track signals are not honored.

RNK separately says mobile information is not shared or sold for marketing. That narrower promise does not erase the broader web-advertising language. The policy also describes access, correction, medical-record, and disclosure-accounting rights without publishing one universal retention period for all categories.

A LegitScript seal appears on RNK pages with an identification number. The public checker did not provide a readable independent result during the review, so the seal is described as provider-presented rather than independently verified certification.

Product pages use broad language about speed, energy, aging, sleep, muscle, metabolism, purity, and satisfaction. Those statements are treated as marketing claims, not proven outcomes or approved indications, because the pages do not link product-specific evidence that substantiates them for RNK's exact formulations.

RNK's consent states that compounded medications are not FDA approved and have not undergone FDA review for safety, effectiveness, or manufacturing quality. The FDA likewise distinguishes compounded products from approved drugs and warns against misleading promotion of unapproved compounded GLP-1 products.

The terms select New York law and AAA consumer arbitration, include jury and class-action waivers with a public-injunction carveout, and cap aggregate liability at $100. No arbitration opt-out procedure was found in the reviewed text.

Commercial status has no bearing on this verdict. The Katalys campaign is pending, the supplied economics are not a consumer benefit, and no issued tracking URL or verified welcome offer is used in this unpublished draft.